Source: University of Alberta
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Entheon Biomedical is pleased to announce the addition of Dr. Andrew  Greenshaw to its advisory board
  • Dr. Greenshaw has significant experience involving research in psychiatry and mental health
  • His scientific interests include computational and biological psychiatry and behavioural neuroscience
  • Entheon is a biotechnology company committed to developing psychedelic therapeutic products to treat addiction and substance use disorders
  • Entheon Biomedical Corp. (ENBI) opened trading at C$0.33 per share

Entheon Biomedical (ENBI) is pleased to announce the addition of Dr. Andrew  Greenshaw to its advisory board.

Dr. Greenshaw is a Fellow of the Royal Society of Arts; a Fellow of the Canadian College of Neuropsychopharmacology (CCNP), for which he served as President from 2000-2002; and a fellow of the Collegium Internationale Neuropsychopharmacologicum (CINP).

Andy served as University of Alberta Associate Vice President (Research) and was a member of the Scientific Advisory Board of the CIHR Institute of Neuroscience Mental Health & Addiction from 2012-2016. Active research includes applications of machine learning and data mining as a member of the University of Alberta computational psychiatry group.

Dr. Greenshaw has significant experience involving research in psychiatry and mental health with a broad range of scientific interests that include computational and biological psychiatry and behavioural neuroscience.

Dr. Greenshaw is the Scientific Director of the APEC Digital Hub for Mental Health, a Director on the Board of Mental Health Research Canada and continues to provide leadership for Canadian Institutes of Health Research grant review panels.

“As we advance our knowledge of mental health through continued research, I look forward to working with Entheon as they continue to clinically develop DMT. Understanding the biological and physiological impacts of psychedelic therapeutics will be a critical component to unlocking the promising potential of psychedelic drug augmentation of therapeutic responses in addiction and mental health,” said Dr. Greenshaw.

“We would like to extend a warm welcome to Andy as he joins the team at Entheon. His knowledge and insight will be paramount as we continue to navigate the development of DMT as a treatment for addiction disorders,” said Chief Executive Officer, Timothy Ko.

“Furthermore, Dr. Greenshaw’s addition brings deep bench strength in the realm of substance use risk, and further strengthens our Advisory Board.”

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N, N-dimethyltryptamine-based psychedelic therapeutic products to treat addiction and substance use disorders.

Entheon Biomedical Corp. (ENBI) opened trading at C$0.33 per share.

More From The Market Herald

" Optimi Health (CSE:OPTI) signs psilocybin supply agreement with Halucenex Life Sciences

Optimi Health (OPTI) has announced a supply agreement with Halucenex Life Sciences Inc., a wholly-owned subsidiary of Creso Pharma of Australia.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.

" Clearmind Medicine (CSE:MIND) and SciSparc report positive results for Psychedelic Combination Treatment

Clearmind Medicine (MND) has released favourable safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.